Tyen Kang's controlled subsidiary obtains preliminary analysis results for Phase IIa clinical trial of CKBA cream for rosacea

每日经济新闻··CN·Read original
3▲1 ▼0Impact / 5
Summary · why it matters

Tyen Kang announced on September 23 that its controlled subsidiary, Jiangsu Bochuangyuan Pharmaceutical Technology Co., Ltd., has recently completed data compilation for the Phase IIa clinical trial of its self-developed Class 1 innovative drug CKBA cream for rosacea. Preliminary analysis results show that 1.50% CKBA cream demonstrated good efficacy and safety in treating moderate to severe papulopustular rosacea. After 16 weeks of treatment, the proportion of subjects whose Investigator's Global Assessment score reached 0 or 1 was 60.00%, or 9 out of 15, and the inflammatory lesion count decreased by 39.06 from baseline, a reduction of 76.40%. No serious adverse events occurred during the trial, nor did any adverse events lead to subject withdrawal, and no new safety risk signals were identified. Only a small number of subjects experienced brief, mild local irritation symptoms, all of which resolved after symptomatic treatment, indicating that CKBA cream is well tolerated.

Impact on assets 1

Others▲ · 1 stocks

Off-coverage companies 1

江苏博创园生物医药科技有限公司Private▲ Positive
Technologyrelevance

The subsidiary itself completed Phase IIa data compilation for its self-developed CKBA cream, with positive efficacy and safety results in rosacea.

© 2026 MarketIVNews